Skip to content
2000
Volume 22, Issue 40
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Nanotechnology has emerged as a promising strategy toward inflammatory bowel disease (IBD) treatment. Nano-sized drug delivery systems exhibit an increased accumulation in inflamed tissues due to their nanometer size and present the ability to overcome the challenging inflamed colonic barriers (i.e. thick mucus layer, disrupted epithelium, altered colonic transit time). Moreover, nanocarriers are able to increase the amount of drug present at the colonic site decreasing their associated systemic side effects and increasing their efficacy. This review aims to analyze the nanoparticulate systems that have been evaluated for IBD treatment based on (i) the strategy followed towards an increased colonic accumulation and/or permeation, (ii) the small or biopharmaceutical antiinflammatory drug encapsulated within the nanocarriers and (iii) the polymer(s) used for their preparation, highlighting the profits and the drawbacks of each of the candidates based on reported results.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612822666160211141813
2016-11-01
2024-11-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612822666160211141813
Loading

  • Article Type:
    Research Article
Keyword(s): chitosan; colitis; colon targeting; Inflammatory bowel disease; nanoparticles; PLGA; TMC
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test